Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacare laboratories pty ltd - trifolium pratense, quantity: 200 mg (equivalent: trifolium pratense, qty 5 g; equivalent: isoflavones (of trifolium pratense), qty 80 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; carnauba wax; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; calcium hydrogen phosphate; hypromellose; iron oxide red; macrogol 400; acacia; potable water; mixed (low-alpha type) tocopherols concentrate; soya oil - maintain/support general health and wellbeing ; help maintain/support emotional wellbeing ; decrease/reduce/relieve symptoms of mild anxiety ; support healthy emotional/mood balance ; helps decrease/reduce/relieve night sweats associated with menopause ; decrease/reduce/relieve symptoms of menopause ; helps reduce occurrence of menopausal symptoms ; decrease/reduce/relieve hot flushes associated with menopause ; decrease/reduce/relieve moodiness/mood swings associated with menopause

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - alendronate sodium, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; macrogol 8000; carrageenan; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

Singapore - English - HSA (Health Sciences Authority)

abbott laboratories (singapore ) private limited - dydrogesterone, micronized (in yellow tablet); estradiol hemihydrate 2.06 mg eqv estradiol (micronised) (in brick red tablet); estradiol hemihydrate 2.06 mg eqv estradiol (micronised) (in yellow tablet) - tablet, film coated - 10 mg - dydrogesterone, micronized (in yellow tablet) 10 mg; estradiol hemihydrate 2.06 mg eqv estradiol (micronised) (in brick red tablet) 2 mg; estradiol hemihydrate 2.06 mg eqv estradiol (micronised) (in yellow tablet) 2 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: gelatin; croscarmellose sodium; butylated hydroxytoluene; colloidal anhydrous silica; sucrose; magnesium stearate; microcrystalline cellulose; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; gelatin; croscarmellose sodium; medium chain triglycerides; microcrystalline cellulose; magnesium stearate; sucrose; butylated hydroxytoluene - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - women:moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia).moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if cyprostat 50mg is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation men:reduction o

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risedronate sodium, quantity: 35 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; iron oxide yellow; macrogol 400; hypromellose; titanium dioxide; iron oxide red; microcrystalline cellulose - treatment of osteoporosis. treatment of glucocorticoid induced osteoporosis. preservation of bone mineral density in patients on long-term corticosteroid therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium monohydrate, quantity: 81.24 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults or by the presence of history of osteoporotic fracture. paget's disease of bone.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - risedronate sodium hemipentahydrate, quantity: 5.74 mg (equivalent: risedronate sodium, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; crospovidone; hyprolose; titanium dioxide; hypromellose; macrogol 8000; colloidal anhydrous silica; iron oxide yellow; macrogol 400 - ? treatment of osteoporosis,? treatment of glucocorticoid-induced osteoporosis,? preservation of bone mineral density in patients on long term corticosteroid therapy